Lyell's syndrome: A report of 16 cases;Le syndrome de lyell: A propos de 16 observations

Tunisie Medicale

Volumn 85, Issue 9, 2007, Pages 801-805

  Boussofara, Lobna ^a   Maalaoui, Houneida ^a   Mebazaa, Amel ^a   Ghariani, Najet ^a   Denguezli, Mohamed ^a   Belajouza, Colandane ^a   Nouira, Rafia ^a  

^a UNIVERSITY OF SOUSSE   (Tunisia)

Author keywords

Drugs; Lyell's syndrome; Toxic epidermal necrolysis; Toxiderma

Indexed keywords

ALLOPURINOL; ANALGAN; ANTIBIOTIC AGENT; ASCORBIC ACID; GENTAMICIN; INDOMETACIN; KETOPROFEN; LINCOMYCIN; METRONIDAZOLE; NORAMIDOPYRINE; OFLOXACIN; PARACETAMOL; PHENOBARBITAL; RODOGYL; SALAZOSULFAPYRIDINE; SPIRAMYCIN; UNCLASSIFIED DRUG; VALPROIC ACID; VISERALGINE FORTE;

ADULT; ARTICLE; BODY SURFACE; CLINICAL ARTICLE; CLINICAL FEATURE; DEATH; DISEASE SEVERITY; FEMALE; HOSPITAL DEPARTMENT; HUMAN; INFECTIOUS COMPLICATION; INTENSIVE CARE; MALE; MEDICAL LITERATURE; MORTALITY; RETROSPECTIVE STUDY; TOXIC EPIDERMAL NECROLYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 37149038149     PISSN: 00414131     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bachot N, Roujeau JC. Imputabilité médicamenteuse en pratique dermatologique quotidienne. Ann Dermatol Venereol 2000;127:542-5.
2. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN : a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53.
3. Chan HL, Stern RS, Arndt KA et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Arch Dermatol 1990;126:43-7.
4. Chan HL. Toxic epidermal necrolysis in Singapore, 1989 through 1993: incidence and antecedent drug exposure. Arch Dermatol 1995;131:1212-3.
5. Roujeau JC, Guillaume JC, Fabre JP, Penso D, Flechet ML, Girre JP. Toxic epidermal necrolysis (Lyell's syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990;126:37-42.
6. Revuz J, Penso D, Roujeau JC et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987;123:1160-5.
7. Stern RS, Chan HL. Usefulness of case report literature in determining drugs responsible for toxic epidermal necrolysis. J Am Acad Dermatol 1989;21:317-22.
8. Paquet P, Arrese JE, Beguin Y, Pierard GE. Clinicopathological differential diagnosis of drug-induced toxic epidermal necrolysis (Lyell's syndrome) and acute graft-versus-host reaction. Curr Top Pathol 2001;94:49-63.
9. Rzany B, Mockenhaupt M, Stocker U, Hamouda O, Schopf E. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. Arch Dermatol 1993;129:101-6.
10. Burge SM, Dawber RP. Stevens-Johnson syndrome and toxic epidermal necrolysis in a patient with systemic lupus erythematosus. J Am Acad Dermatol 1985;13:665-6.
11. Sehgal VN, Srivastava G. Toxic epidermal necrolysis (TEN) Lyell's syndrome. J Dermatol Treat 2005;16:278-86.
12. Becker DS. Toxic epidermal necrolysis. Lancet 1998;351:1417-20.
13. Criton S, Devi K, Sridevi PK, Asokan PU. Toxic epidermal necrolysis a retrospective study. Int J Dermatol 1997;36:923-5.
14. Pirrung MK. Management of toxic epidermal necrolysis. J Intraven Nurs 2001;24:107-12.
15. Parsons JM. Management of toxic epidermal necrolysis. Cutis 1985;36:305-7.
16. Paquet P. Les médicaments responsables de nécrolyse épidermique toxique. Thérapie 1993;48:133-9.
17. Revuz J, Roujeau JC, Guillaume JC, Penso D, Touraine R. Treatment of toxic epidermal necrolysis. Creteil's experience. Arch Dermatol 1987;123:1156-8.
18. Tegelberg-Stassen MJ, Van Vloten WA, Baart de la Faille H. Management of nonstaphylococcal toxic epidermal necrolysis : follow-up study of 16 case histories. Dermatologica 1990;180:124-9.
19. Chave TA, Mortimer NJ, Sladden MJ, Hall AP, Hutchinson PE. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005;153:241-53.
20. Egan CA, Grant WJ, Morris SE, Saffle JR, Zone JJ. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999;40:458-61.
21. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol 2003;139:39-43.
22. Ying S, Ho W, Chan HH. Toxic epidermal necrolysis: 10 years experience of a burns centre in Hong Kong. Burns 2001;27:372-5.
23. Chan HL. Observations on drug-induced toxic epidermal necrolysis in Singapore. J Am Acad Dermatol 1984;10:973-8.
24. Westly ED, Wechsler HL. Toxic epidermal necrolysis. Granulocytic leukopenia as a prognostic indicator. Arch Dermatol 1984;120:721-6.
25. Honari S, Gibran NS, Heimbach DM et al. Toxic epidermal necrolysis (TEN) in elderly patients. J Burn Care Rehabil 2001;22:132-5.
26. Garcia-Doval I, Le Cleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000;136:323-7.